DRUG
Eptifibatide
Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients
Status
Unknown
Phase
Phase 2
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct intracoronary injection, promotes (in vitro) clot disaggregation. It remains unclear if it is of superior benefit than the routine intravenous administration of these agents. In patients presenting with acute myocardial infarction, and undergoing primary coronary intervention, intracoronary administration of Eptifibatide may increase local drug concentration by several orders of magnitude and promote clot disaggregation with a minimal increase in systemic drug concentration, and in that way enhancing myocardial perfusion and survival.
Full detailed description
Patients will be randomized, prospectively, single blinded into one of two arms:1)intravenous administration of Eptifibatide and 2) intracoronary administration. The primary end-point will be the angiographic achievement of TIMI 3 flow at the infarct related artery and TIMI myocardial perfusion grade (blush) and the electrocardiographic surrogate of myocardial perfusion the ST segment resolution. The secondary end-points will be the occurrence of bleeding or hemorrhagic complication according to TIMI classification and the LVEF at one month compared with baseline
Interventions
Treatment arms and agents.
DRUG
Eptifibatide
Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
Timeline
From registration to results.
First posted
Jul 24, 2009
Study start
Aug 2009
Primary completion
Feb 2010
Study completion
Feb 2010
Results posted
Not reported
Registry updated
Jul 24, 2009
Outcomes
What the study measures.
Primary outcomes
Coronary angiography
Time frame · At the time of the procedure
Secondary outcomes
Electrocardiogram
Time frame · 90 min after the procedure
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Acute myocardial infarction candidate for primary coronary angioplasty, presenting within 12 hours of onset of pain and ability to clearly identified only one infarct related artery. Exclusion Criteria: * Contraindications for antiplatelet therapy such as bleeding disorders, * Thrombocytopenia, * Severe uncontrolled hypertension, * Recent stroke (\<6 months), * Intracranial hemorrhage at any time * Patients after recent major surgery (\<30 days), * Previous myocardial infarction * Previous revascularization either by CABG or PCI and 9)patients presented with cardiogenic shock.
Study locations
1 registered sites.
Israel. Showing up to 24 locations stored in the fast local snapshot.
Assaf Harofeh Medical Center
Beer Yakov, Beer Yakov, Israel
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Eptifibatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Xinqiao Hospital of Chongqing · Acute Ischemic Stroke
Phase 3
Not yet recruiting
786
2026-01
Multi-arm Optimization of Stroke Thrombolysis
Washington University School of Medicine · Acute Ischemic Stroke
Phase 3
Completed
514
2025-02
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Organon and Co · Myocardial Ischemia · Acute Coronary Syndrome
Phase 3
Completed
9,406
2024-05
Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic
Baylor College of Medicine · Acute Ischemic Stroke
Phase 1 / Phase 2
Unknown
30
2022-06
Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Medstar Health Research Institute · ST-elevation Myocardial Infarction · Acute Myocardial Infarction
Not applicable
Withdrawn
0
2021-07
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Medicure · Myocardial Infarction · Acute Coronary Syndromes
Phase 2
Completed
535
2021-05
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
University of Alabama at Birmingham · Acute Coronary Syndrome · Angina, Unstable
Phase 2
Completed
100
2020-05
Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)
Ministry of Science and Technology of the People´s Republic of China · Acute Ischemic Stroke
Phase 3
Unknown
220
2019-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.